Versatility of USP18 in physiology and pathophysiology

Paulina Dziamałek-Macioszczyk; Joanna  Haraźna; Tomasz Stompór

doi:10.18388/abp.2019_2844

Versatility of USP18 in physiology and pathophysiology

Paulina Dziamałek-Macioszczyk Department of Nephrology, Hypertension and Internal Medicine, University of Warmia and Mazury, Olsztyn, Poland https://orcid.org/0000-0002-0731-2993
Joanna Haraźna Department of Pathophysiology, University of Warmia and Mazury, Olsztyn, Poland https://orcid.org/0000-0003-0124-0543
Tomasz Stompór Department of Nephrology, Hypertension and Internal Medicine, University of Warmia and Mazury, Olsztyn, Poland https://orcid.org/0000-0002-3944-0850

DOI: https://doi.org/10.18388/abp.2019_2844

Abstract

Ubiquitin-specific peptidase 18 (USP18) is a multifunctional protein and its roles are still being investigated. This enzyme removes ubiquitin-like molecules from their substrates and the only known interferon-stimulated gene 15 (ISG15) specific protease. Apart from its enzymatic function, it also inhibits interferon type I and III signalling pathways. USP18 is known to regulate multiple processes, such as: cell cycle, cell signalling and response to viral and bacterial infections. Moreover, it contributes to the development of several autoimmune diseases and carcinogenesis, and recently was described as a cardiac remodelling inhibitor. This review summarizes the current knowledge on USP18 functions, highlighting its contribution to the development of heart failure, given the fact that this disease’s etiology is now considered to be inflammatory in nature.

pdf
html

Published

2019-11-20

Issue

Vol. 66 No. 4 (2019): Part I and Part II - FEBS

Section

Articles

Acta Biochimica Polonica is an OpenAccess quarterly and publishes four issues a year. All contents are distributed under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY 4.0) license. Everybody may use the content following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.